AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$KYMR

Mainolfi Nello sold $6.0M of KYMR

Mainolfi Nello (Chief Executive Officer) sold 50,000 shares of Kymera Therapeutics, Inc. (KYMR) at $119.00 ($5.95M total) on 2026-07-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mainolfi Nello
Published Jul 8, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 8, 2026, 12:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KYMR
Neutral
high confidence
Mentioned
$KYMR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KYMRNeutralLow
01

Why it matters

The disclosure updates the record of insider transactions and may influence short-term sentiment, but it does not introduce new company fundamentals (no guidance, trial, deal, or regulatory action mentioned).

02

Market read

Traders may monitor insider activity for sentiment, but this specific filing is unlikely to drive a fundamental repricing.

03

What to watch

The article provides no context on total insider holdings, prior sale cadence, or whether proceeds relate to taxes/diversification; those factors can materially change interpretation.

Relevance 5/10Novelty 3/10Timing: Filed 2026-07-07 after-hours; reflects insider sale details for KYMR.

Background

This is an SEC Form 4 reporting an officer/director open-market sale by Kymera Therapeutics CEO Mainolfi Nello, explicitly under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$KYMRNeutralHigh confidence
Context

Kymera Therapeutics CEO Mainolfi Nello sold 50,000 shares on 2026-07-07 at $119/share under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arranged plan and no accompanying operational or guidance change.

Market effects

Sector

Minimal—single-company insider liquidity disclosure without sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as caution about near-term fundamentals.

Key entities

  • issuer
    Kymera Therapeutics, Inc.

    Subject of the Form 4 insider transaction; CEO sold shares under a 10b5-1 plan.

  • insider
    Mainolfi Nello

    CEO and officer/director who executed the reported sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KYMR insider trading history →

Related articles

$KYMRMed

Kymera (KYMR) Q3 2026 Earnings Call Transcript

Kymera (KYMR) reported Q3 2026 earnings, highlighting progress in its pipeline, including Phase IIb data for KT-621 in atopic dermatitis (AD) expected by year-end. The BROADEN 2 study's placebo-controlled portion is complete, with 98% of eligible patients enrolling in the open-label extension. The company also discussed market research indicating a demand for safe, effective oral treatments for AD.

finance.yahoo.com
$KYMRMed

Kymera Therapeutics Q3 Earnings Call Highlights

Kymera Therapeutics reported Q3 results, highlighting 98% inhibition of TLR7/8-stimulated interferon-beta levels and positive phase I data for KT-579. The company plans a phase Ib lupus study (LUMORA) in early 2027. KT-621 is expected to show atopic dermatitis efficacy comparable to dupilumab. Q3 R&D expenses were $128.5M, with cash position of $1.6B providing runway into 2029.

finance.yahoo.com
$KYMRMedAI 8/10

Kymera Q3 2026 slides: IRF5 degrader shows 90%+ target engagement

Kymera Therapeutics (KYMR) reported Q3 2026 results, missing earnings but showing 90%+ target engagement for its IRF5 degrader KT-579. The stock rose 3.46% premarket. The company reported a net loss of $132M, up from $82.2M YoY, with R&D expenses increasing 73%. Kymera has $1.6B in cash, providing a runway into 2029. KT-579 showed promising Phase 1 data, with significant biomarker reductions and a favorable safety profile.

investing.com
$KYMRHigh

Kymera Therapeutics 3Q 2026: Revenue $0 Net loss $132M, EPS $(1.32) — 10-Q Summary

Kymera Therapeutics reported 3Q 2026 revenue of $0, down from $2.8M a year earlier, and a net loss of $132M, or $(1.32) per share, compared to a net loss of $82.2M, or $(0.94) per share, in the prior-year quarter. The company's collaboration revenue for the nine months increased to $99.4M, driven by partnerships with Gilead and Sanofi. Research and development spending rose 49%, primarily due to expanded program work and personnel investments.

tradingview.com
$KYMRHighAI 8/10

Kymera reports phase 1 data for KT-579, plans lupus trial

Kymera Therapeutics (KYMR) reported phase 1 trial results for KT-579, showing significant IRF5 degradation and biomarker reductions. The company plans a phase 1b lupus trial in 2027. Q3 2026 net loss was $132.0M, up from $82.2M in 2025, with R&D expenses increasing. Cash reserves are $1.6B, expected to last into 2029. Updates on other clinical trials were also provided.

investing.com